mk-0482
merck
['mk-0482', 'myeloid']
a phase i trial of mk-0482, an anti-ilt3. ilt3 is an inhibitory receptor on monocytic myeloid cells. myositis occurred in 2 pts and one was grade 5. 0 prs in monotherapy arm with some activity (orr -15%) in combination arm. #asco22 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own